Stocktoria
Polyrizon Ltd. PLRZ
Nasdaq · stock · Surgical & Medical Instruments & Apparatus · website · IPO 2024-10-29
Polyrizon Ltd. financials (annual)
Bars are annual figures from 2023 to 2025; red bars are negative (a loss or cash outflow).
| Metric | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| R&D expense | $2.1M | $534,000 | $332,000 |
| Operating income | -$6.2M | -$1.3M | -$635,000 |
| Net income | -$3.3M | -$1.5M | -$600,000 |
| EPS (diluted) | $4.90 | $805.20 | $494.40 |
| Operating cash flow | -$4.5M | -$1.1M | -$537,000 |
| Free cash flow | -$4.5M | — | — |
| Cash & equivalents | $1.3M | $2.6M | $4,000 |
| Total assets | $21.4M | $5.5M | $559,000 |
| Shareholders' equity | $21.0M | $5.3M | -$191,000 |
Growth · year-over-year
| Metric | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| EPS growth | -99.4% | +62.9% | — |
Each column is the change versus the prior fiscal year. Growth off a negative or zero base is shown as “—”. CAGR is the compound annual revenue growth across the years shown.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.